Iduronate-2-sulfatase Inhibitors
1 drugsAbout Iduronate-2-sulfatase
Iduronate-2-sulfatase (IDS) is a lysosomal enzyme that breaks down glycosaminoglycans (GAGs) by removing sulfate groups from iduronic acid. Its deficiency leads to GAG accumulation, causing a lysosomal storage disorder.
IDS is a drug target because its deficiency causes significant disease. Currently, there is no genetic evidence data available for this target.
ELAPRASE (Takeda) is the only FDA-approved drug targeting IDS, representing a biologic (other) modality. The therapeutic area for IDS-targeting drugs is classified as 'Other'.
Top Iduronate-2-sulfatase Drugs
Takeda is the only company with an approved drug targeting IDS.
The market's concentration with a single player indicates high barriers to entry or limited commercial opportunity.
Iduronate-2-sulfatase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Iduronate-2-sulfatase, using enzyme modality.
The lack of modality diversity suggests an opportunity for novel therapeutic approaches beyond enzyme replacement.
Iduronate-2-sulfatase Clinical Trials 11 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Iduronate-2-sulfatase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 4 | 2 | 0 | 2 | 100% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved Iduronate-2-sulfatase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Iduronate-2-sulfatase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Iduronate-2-sulfatase Drug Approval Timeline (2006 - 2006)
The first and only drug, ELAPRASE, was approved in 2006.
The lack of recent approvals suggests market saturation or challenges in developing improved therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 5 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Iduronate-2-sulfatase. A trial counts if an approved drug acting on Iduronate-2-sulfatase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.